Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation ...

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinibREDWOOD CITY, Calif., ...

Management of older adults with type 2 diabetes and chronic kidney disease is complex. These individuals often have multiple comorbidities, take several medications, and are at increased risk of ...

New study examines benefits of continuous glucose monitoring (CGM) in people with type 2 diabetes (T2D) using glucagon-like ...

While the genesis of typical modern medical technologies focuses on a specific design element or research protocol, for Glucotrack Inc. (NASDAQ: GCTK), the basis of innovation begins at the human ...

The American Diabetes Association’s 85th Scientific Sessions is almost here, and Medscape is ready to make an impact in the ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, ...